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AbstrACt
Introduction Patients with congenital heart disease 
often need repeated operations throughout life to 
replace the pulmonary valve. Valve replacement with 
‘injectable’ self-expanding valves (which is performed 
‘off pump’ without the use of cardiopulmonary bypass, 
CPB) may result in quicker recovery and lower risk 
of major complications than valve replacement with 
conventional valves (which is performed ‘on pump’ with 
the use of CPB).
Methods and analysis We are conducting a 
multicentre, single-blind randomised controlled 
trial in patients with congenital heart disease and 
aged between 12 and 80 years. We will randomise 
participants in a 1:1 ratio to receive either ‘off pump’ 
injectable pulmonary valve replacement or ‘on pump’ 
conventional pulmonary valve replacement. The primary 
outcome will be the difference between the groups 
with respect to post-surgery blood loss (as measured 
by chest drain volume) in the first 24 hours. Secondary 
outcomes will include in-hospital outcomes (intensive 
care unit stay, inotropic/vasodilator support, chest 
drain volume in the first 12 hours post-surgery, time of 
readiness for extubation, blood products used in the 
first 24 hours post-surgery, time of fitness for discharge, 
valve and heart function 6 months post-surgery 
(assessed using cardiovascular magnetic resonance and 
ECHOCARDIOGRAPHY) and health-related quality of life 6 
weeks and 6 months post-surgery.
Ethics and dissemination This trial has been approved 
by the South West Exeter Research Ethics Committee. 
Findings will be shared with participating hospitals and 
disseminated to the academic community through peer 
reviewed publications and presentation at national and 
international meetings. Patients will be informed of the 
results through patient organisations and newsletters to 
participants.
trial registration number ISRCTN23538073
IntroduCtIon   
background and objectives
Most children born with complex congenital 
heart disease now reach adulthood. Post-sur-
gery mortality following surgical correction, 
of tetralogy of Fallot, for example, has fallen 
from 5.5% in 19801 to 0% in 2016.2 However, 
as long-term survival has improved late 
sequelae have become evident. Many of the 
patients operated on for tetralogy of Fallot 
and other forms of pulmonary valve disease 
require multiple operations throughout 
life to repair or replace poorly functioning 
pulmonary valves.
The standard operation for pulmonary 
valve replacement (PVR) involves opening 
strengths and limitations of this study
 ► This trial is the first randomised controlled trial 
(RCT) to assess the effectiveness of injectable tissue 
valves versus conventional tissue valves for pulmo-
nary valve replacement (PVR).
 ► This is a multicentre RCT, with computer-generated 
concealed randomisation and participant blinding to 
minimise bias.
 ► We are including both children and adults (age range 
12–80 years) to ensure the findings will be gener-
alisable to a wide group of patients who need PVR.
 ► Although clinicians cannot be blinded to the pa-
tient’s treatment allocation, we will minimise bias by 
pre-defining all procedures for data collection and 
applying these to all participants in the same way.
 ► The primary and many of the secondary endpoints 
are clinical outcomes, based on objective criteria, 
which are important to patients, clinical teams and 
the NHS.
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the chest, exposing the heart and using cardiopulmo-
nary bypass (CPB), (‘on pump’). CPB is a technique that 
temporarily takes over the function of the heart and lungs 
(pumping blood and oxygen through the body) and occa-
sionally involves stopping the heart during surgery. CPB is 
associated with complications such as excessive bleeding 
and reperfusion injury in cases where the heart has to be 
stopped (damage to heart tissue occurs when the blood 
supply returns to the heart).
Injectable tissue valves (BioPulmonic, Biointegral 
Surgical) have been developed to replace conventional 
tissue valves for PVR. Injectable tissue valves can be 
implanted without the use of CPB (ie, ‘off pump’) and 
with less dissection of the heart. Case reports and small 
case series (<12 patients)3–10 have shown that injectable 
tissue valves are easy to implant and have satisfactory 
function. Pilot data have shown shorter operating time 
(2 hours less) and less blood loss (over 400 mL less) and 
blood product requirement (3 units less) in 6 ‘off-pump’ 
injectable pulmonary valve replacement (IPVR) patients 
compared with 7 ‘on pump’ PVR patients. No patient 
had a paravalvular leak (leak around the replaced valve) 
or more than mild pulmonary regurgitation at early 
follow-up, suggesting that IPVR is a safe procedure.11 
There are no randomised controlled trials (RCTs) that 
have evaluated IPVR versus PVR.
We are conducting an RCT to determine whether 
IPVR leads to less blood loss, faster recovery, lower risk 
of post-surgery complications and good valve function in 
patients who need an operation to replace their pulmo-
nary valve. We could not consider percutaneous tran-
scatheter pulmonary valve replacement (TPVR), which 
is performed via cardiac catheterisation and therefore 
does not require open-heart surgery, because current 
TPVR valve sizes are only suitable for patients with a right 
ventricular outflow tract (RVOT) diameter of ≤27 mm 
which would exclude >80% of our eligible population.12 13 
Further, all eligible patients will have native outflow tracts 
that are too distensile for robust fixation of a percuta-
neous valve.
AIMs And objECtIvEs
The main aim of the InVITe trial is to compare IPVR 
versus PVR in patients who need PVR. The objective is to 
estimate the difference between the groups with respect 
to:
1. Post-surgery blood loss (as measured by chest drain 
volume) in the first 24 hours (primary outcome);
2. A range of clinical post-surgery outcomes (intensive 
care unit (ICU) stay, inotropic/vasodilator support, 
chest drain volume in the first 12 hours, time until 
ready for extubation, blood products used in the first 
24 hours, fitness for discharge (FFD) and valve-related 
complications during follow-up);
3. Heart and valve function assessed using cardiovascular 
magnetic resonance (CMR) and Echocardiography;
4. Health related quality of life (HRQoL).
MEthods
trial design and population
The InVITe trial is an early phase, multicentre, RCT 
comparing IPVR with PVR. We will recruit patients being 
referred for PVR at University Hospitals Bristol NHS 
Foundation Trust and University Hospitals Southampton 
NHS Foundation Trust.
Eligibility criteria
Potential participants will be eligible if they are:
1. Aged between 12 and 80 years.
2. Have a valve size between 25–31 mm.
3. Undergoing any of the following as either a first or a 
redo procedure:
a. Replacement of the pulmonary valve;
b. Replacement of the pulmonary valve with atrial sep-
tal defect which is amenable to closure via cardiac 
catheter or;
c. Replacement of the pulmonary valve with right 
ventricular outflow tract (RVOT) reconstruction 
that does not require CPB if using an injectable 
valve.
Potential patients will be ineligible if they are:
1. Prisoners or adults lacking capacity to consent.
2. Aged between 12 and 15 years and under the care of 
social services.
3. Undergoing an additional procedure that requires 
the use of CPB (eg, pulmonary valve or artery steno-
sis requiring patch reconstruction, intra-cardiac shunt, 
RVOT reconstruction requiring CPB, other anatomi-
cal heart corrections).
4. Diagnosed with active endocarditis.
5. Unwilling to undergo surgery involving a porcine 
product.
6. Unable to assent/consent.
Patient approach and consent
We will identify potential participants from clinic 
lists (elective patients) and theatre schedules (urgent 
patients) and they will be given an invitation letter 
and patient information leaflet (PIL) suitable to 
their age group. Parent(s)/guardian(s) of potential 
participants 12–15 years old will be given an invita-
tion letter and parent/guardian information leaflet 
(P/GIL). Most patients and parent(s)/guardian(s) 
will have at least 24 hours to consider whether they 
would like to participate, although in some cases this 
time interval may be shorter; for example, patients 
admitted from other hospitals without prior notifica-
tion to the research team. Written informed consent/
assent will be obtained from the patients and/or their 
parent(s)/guardian(s) (where appropriate) prior 
to inclusion in the trial. Figure 1 shows the patient 
pathway.
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trial interventions
For both operations the heart will be exposed through 
a standard incision for a heart operation (median 
sternotomy).
For IPVR operations a self-expanding no-react inject-
able BioPulmonic valve (Biointegral Surgical) will be 
used. The main pulmonary artery and the front of the 
heart will be dissected out. A purse-string stitch will be 
placed in the front of the heart and the size of valve 
required will be confirmed using an echocardiogram. 
If the main pulmonary artery is too big, it will be made 
smaller using a stitch to narrow it down. The valve 
injector will be inserted into the heart through the 
purse string and the valve will be deployed and sewn 
into position using 3 fixation stitches. If the patient 
becomes unstable during the surgery, CPB will be insti-
tuted. The position and function of the valve will be 
confirmed using transoesophageal echocardiography. 
The operation will then be completed in the standard 
manner.
For PVR operations, the type of tissue valve used will be 
according to the usual practice at the participating site and 
may include stented tissue valves (in adults particularly) 
or homografts (in children particularly). The heart will 
be freed from the scar tissue and the patient put on CPB. 
The pulmonary artery will be opened and the old valve 
removed. A new valve of the correct size will be sewn into 
place. In some cases the heart may need to be stopped 
for a short period of time. A patch may also be necessary 
to close the heart over the new valve. Once this has been 
completed and the heart has recovered from the effects 
of cardioplegic arrest, CPB will be discontinued and the 
operation will be completed in the standard manner.
All other aspects of participant’s care will be performed 
according to standard practice.
Participants will be followed up at 6 weeks (question-
naire completion) and 6 months (questionnaire comple-
tion, Echocardiography and CMR) post-surgery. The 
6-month Echocardiography and CMR will coincide with 
routine hospital follow-up; so we expect minimal loss 
to follow-up. A 6-month follow-up period will provide 
adequate data to inform early recovery.
randomisation
Trial allocations will be generated by a computer using 
block randomisation with varying block sizes. Participants 
Figure 1 Trial schema showing the recruitment pathway with the number of patients to be recruited, anticipated eligibility and 
recruitment rates.
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will be randomly assigned in a 1:1 ratio and randomisa-
tion will be stratified by centre. If a participant’s opera-
tion is unexpectedly rescheduled, the trial number and 
randomised allocation will be retained.
trial outcomes
The primary outcome will be post-surgery blood loss as 
measured by the chest drainage volume in the first 24 
post-surgical hours. The secondary outcomes include:
1. Post-surgery time to ‘readiness for extubation’. The 
following criteria will be documented at the time of 
extubation (when all criteria should be met): normal 
temperature, cardiovascular system stable, no met-
abolic imbalance, blood loss decreasing and below 
a defined rate, able to clear respiratory secretions, 
patient awake, no residual muscle paralysis and ade-
quate analgesia;
2. Length of ICU stay;
3. Inotropic/vasodilator support;
4. Chest drain volume in the first 12 post-surgical hours;
5. Blood products used in the first 24 post-surgical 
hours (red blood cells, fresh frozen plasma, platelets, 
human albumin solution, cryoprecipitate) and bleed-
ing events that may or may not lead to re-operation;
6. Post-surgery time to FFD, defined as when all of the 
following criteria are met: normal temperature, pulse 
and respiration, normal oxygen saturation on air, 
normal bowel function, physically mobile ;
7. CMR assessment of valve and heart function at 
6 months, defined as presence and degree of 
pulmonary regurgitation, end-diastolic volume and 
right ventricular ejection fraction;
8. Echocardiographic assessment of valve function at 
routine follow-up at 6 months, defined as presence 
and degree of pulmonary regurgitation and residual 
valve stenosis, measured as peak velocity through the 
valve;
9. HRQoL at 6 weeks and 6 months post-surgery 
(EuroQol EQ-5D in patients ≥18 years and EQ-5D-Y 
in patients <18 years, SF36 in patients ≥18 years and 
child health questionnaire in patients <18 years);
10. Valve-related complications up to 6 months 
post-surgery.
data collection
The schedule of data collection is shown in table 1. Data 
will be collected from medical notes and hospital records, 
entered onto a bespoke database and stored on a secure 
server. Access to the database will be limited to authorised 
personnel. Data will be collected and retained in accor-
dance with the UK Data Protection Act 2018.
blinding
We will blind participants to their treatment alloca-
tion and assess the efficacy of blinding at 6 weeks and 6 
months post-surgery via questionnaires. We will record 
any instances of unblinding. Staff responsible for the care 
of the patient will be aware that the patient is blinded 
and asked not to disclose the patient’s treatment allo-
cation. It will not be possible to blind surgeons, staff 
responsible for the care of the patient or research nurses 
Table 1 Schedule of data collection
Data item Pre-surgery
During 
surgery
Post-surgery (up 
to and including 
discharge)
6 weeks post-
surgery
6 months 
post-surgery
Screening and consent data ✓
Baseline data (patient demographics, medical 
history, medications)
✓
Cardiovascular magnetic resonance imaging ✓ ✓
Echocardiography ✓ ✓
Randomisation allocation ✓
Intervention (injectable pulmonary valve 
replacement /PVR)
✓
Inotropic/vasodilator support ✓
Chest drain volume in the first 12 and 24 hours ✓
Blood products used in the first 24 hours ✓
Readiness for extubation ✓
Intensive care unit stay ✓
Fitness for discharge ✓
Health related quality of life ✓ ✓
Follow-up questionnaires to collect all serious 
post-surgery complications and safety data
✓ ✓
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to the participant’s treatment allocation. Details of the 
procedure are needed to order an injectable valve of the 
required size and also need to be recorded in the medical 
notes.
sample size calculation
A sample size of 60 (30 per group) will have 80% power to 
detect an approximate 50% reduction in chest drainage 
volume (effect size on logarithmic scale of −0.73) over the 
first 24 hours at a 5% significance level (two-tailed). This 
target difference is large but is entirely consistent with 
the >70% reduction observed in a small non-randomised 
comparison of patients who had IPVR and PVR.11
statistical analysis
The trial will be analysed on an intention-to-treat basis, 
that is, outcomes will be analysed according to the treat-
ment allocation. Any non-adherence to the allocated 
group will be documented. The primary outcome (chest 
drainage volume in the first 24 post-surgical hours) will 
be analysed using linear regression (on the logarithmi-
cally transformed values as the distribution is expected 
to be skewed). All secondary outcomes will yield either 
binary, quantitative, time-to-event or longitudinal data, 
and will be analysed using logistic regression (binary 
outcomes), linear regression (quantitative outcomes), 
survival methods (time-to-event outcomes). Outcomes 
with repeated measures (longitudinal data) will be anal-
ysed using mixed models which allow for unbalanced 
data. Alternative correlation structures will be considered 
and the sensitivity of the results to the choice of the struc-
ture examined. Analyses will be adjusted for the centre 
(stratification factor). Outcomes will be reported as effect 
sizes with 95% CIs.
Patient and public involvement
Patients were not actively involved in the design of the 
study. However, the PIL for patients aged 12–15 years 
was reviewed by three children and their families (the 
children were members of the public who did not have 
congenital heart disease) to confirm the acceptability of 
the study and the content and format of the PIL as being 
appropriate for this age group. Changes to the PIL were 
made based on their feedback to ensure the PIL was suit-
able for this age group.
Patients will be informed of the results through patient 
organisations and through a summary report for partic-
ipants. The results summary for participants will be 
designed with input from the Cardiovascular Biomed-
ical Research Centre patient public involvement advisory 
group. 
risk of bias
We have designed the trial to minimise the risk of 
bias. Participants will be randomised after eligibility is 
confirmed. Participants will be blinded to treatment 
allocation to ensure that patient-reported outcomes 
(HRQoL) are not influenced by any perceptions about 
which valve is better.
Although surgeons, staff responsible for the care of the 
patient and research nurses will not be blinded to the 
treatment allocation, all surgical procedures will follow 
standard protocols. We will pre-define all procedures and 
data collection required for participant follow-up and 
apply the procedures to all participants in the same way.
We expect minimal missing outcome data as most 
outcome data will be collected during the participants’ 
hospital stay. We will maintain contact with participants 
during follow-up (eg, contacting patients with overdue 
questionnaires) to maximise questionnaire comple-
tion rates and attendance at the 6-month follow-up 
appointment.
We have pre-specified all outcomes and will write a 
detailed analysis plan before the database is closed and 
comparisons between groups are investigated to prevent 
selective reporting of results.
EthICs
The trial is managed by the Clinical Trials and Evaluation 
Unit Bristol (CTEU Bristol) and sponsored by University 
Hospitals Bristol NHS Foundation Trust ( www. uhbristol. 
nhs. uk/ research- innovation/). Participants and their 
parents/guardians (where applicable) have the right 
to withdraw at any time and if they do withdraw, will be 
treated according to their hospitals’ standard procedures. 
Participants who choose to withdraw from the study will 
be asked if we can retain and continue to use any data 
already collected and whether they are willing to partici-
pate in the trial follow-up.
Changes to the protocol since rEC approval
We made three major changes to the protocol before 
recruitment began. First, we decided to blind partici-
pants to ensure validity of the patient-reported outcome 
data. Second, we decided that it was not feasible to blind 
the research nurses to the treatment allocation as they 
would be required to order the valves. Third, initially 
we intended to establish a Data Monitoring and Safety 
Committee to oversee the trial. Given that the trial has a 
relatively low target sample size, a short follow-up period 
and we expect very few serious adverse events, it is hard 
to conceive of an interim analysis (eg, after 50% of the 
participants have been recruited) with sufficient power 
to identify a safety issue that would require action to be 
taken. We concluded, therefore, that it was sufficient for 
the safety data to be reviewed by the Trial Management 
Group and Trial Steering Committee for Cardiovascular 
Studies, a sub-group of the University Hospitals Bristol 
NHS Foundation Trust Cardiovascular Research Board. 
Shortly after opening to recruitment, we made one major 
change to the protocol, to extend the baseline data collec-
tion to include the pre-surgery echocardiographic and 
CMR results. Finally, protocol and study documents 
have been amended to allow the central analysis of CMR 
data. Version 6.0 (dated 02/07/2018) of the protocol is 
currently in use. The relevant regulatory approvals will 
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be obtained for amendments to the protocol and study 
information leaflets. Relevant parties (eg, investigators at 
participating sites) will be informed via email. If changes 
are made to the study processes, participants consent will 
be obtained again, if necessary.
recruitment and issues experienced
The InVITe trial opened to recruitment in April 2016 in 
Bristol and the first patient was recruited in July 2016. 
Recruitment in Southampton opened in January 2017. 
To date, we have identified 38 eligible patients and 17 
patients have consented, 13 of whom have had surgery (8 
of these have completed follow-up).
Recruitment has been slower than anticipated for a 
number of reasons. Several sites were approached to 
participate in the study but declined. Reasons given 
included a reluctance to depart from the traditional care 
pathway for high-risk patients, excessive treatment costs 
involved and the motivation of surgeons to undertake 
the study. In the recruiting sites, the number of patients 
being referred for a PVR is lower than expected and the 
number of patients who do not meet the eligibility criteria 
is higher than originally anticipated.
Additionally, organising training in IPVR surgery 
has proved logistically challenging. As part of the trial, 
surgeons were required to complete two training cases 
which were supervised by a leading expert in IPVR 
surgery. It took longer than expected for all participating 
surgeons to complete the required training. During this 
time, patients whose operations were scheduled at short 
notice could not be approached. In Bristol, there were 
initially two participating surgeons. To help improve 
recruitment rates, we invited an additional surgeon to 
participate in the study.
dIssEMInAtIon of fIndIngs
We will present our findings at international meetings 
and in peer-reviewed publications. We will inform the 
public through patient organisations and through news-
letters to participants.
dIsCussIon
The InVITe trial will be the first RCT to compare IPVR 
with PVR in patients requiring replacement of the pulmo-
nary valve. To our knowledge, the trial remains the only 
RCT (published or registered) comparing IPVR with 
conventional PVR. The proposed trial should, therefore, 
contribute significantly to the understanding of IPVR and 
inform larger RCTs in the future.
Most individuals with congenital heart disease need 
repeated operations to replace the pulmonary valve. For 
example, if a child needs a pulmonary valve replaced, 
it is more likely that the prosthetic valve will need to be 
replaced more than once as the tissue valve will wear 
out. It is therefore essential to look at ways to minimise 
harm and improve the quality of life after surgery. The 
main benefits for patients due to IPVR are believed to be 
a quicker recovery as well as a lower risk of post-surgery 
morbidity, including serious but rare (<5%) complica-
tions. These benefits to patients are expected to translate 
into benefits for the NHS with fewer resources needed 
during and after the operation (shorter surgery time and 
no CPB costs, shorter duration of ventilation, intensive 
care and overall hospital stay, fewer blood products and 
fewer resources required to treat comorbidity).
The main strengths of our trial are the inclusion of both 
children and adults which will ensure that our findings 
are generalizable to a wide range of patients, the collec-
tion of data on a wide range of primary and secondary 
outcomes which could inform the selection of outcomes 
in a future larger RCT and the inclusion of a patient-re-
ported outcome (HRQoL) which is important in a popu-
lation that needs repeated operations.
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